ISDA

Entry Detail

PDB ID:

9FBY

Keywords:

Title:

N-TERMINAL BROMODOMAIN OF HUMAN BRD4 with (5-(4-chloro-1-((tetrahydro-2H-pyran-4-yl)methyl)-1H-imidazol-2-yl)-1,3-dimethylpyridin-2(1H)-one

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2024-05-14

Release Date:

2024-06-26

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.85 Å

R-Value Free:

0.21

R-Value Work:

0.18

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Bromodomain-containing protein 4
Chain IDs:A
Chain Length:127
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:O60885 Pfam ID:PF00439

Ligand Molecules

A1IB5

EDO

Primary Citation

Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787.

Hirst, D.J, Bamborough, P, Al-Mahdi, N, Angell, D.C, Barnett, H.A, Baxter, A, Bit, R.A, Brown, J.A, Chung, C.W, Craggs, P.D, Davis, R.P, Demont, E.H, Ferrie, A, Gordon, L.J, Harada, I, Ho, T.C.T, Holyer, I.D, Hooper-Greenhill, E, Jones, K.L, Lindon, M.J, Lovatt, C, Lugo, D, Maller, C, McGonagle, G, Messenger, C, Mitchell, D.J, Pascoe, D.D, Patel, V.K, Patten, C, Poole, D.L, Shah, R.R, Rioja, I, Stafford, K.A.J, Tape, D, Taylor, S, Theodoulou, N.H, Tomlinson, L, Wall, I.D, Wellaway, C.R, White, G, Prinjha, R.K, Humphreys, P.G.Show

J.Med.Chem. 67 10464 10489 (2024)

PMID: 38866424 DOI: 10.1021/acs.jmedchem.4c00959

Abstact

The bromodomain and extra terminal (BET) family of bromodomain-containing proteins are important epigenetic regulators that elicit their effect through binding histone tail N-acetyl lysine (KAc) post-translational modifications. Recognition of such markers has been implicated in a range of oncology and immune diseases and, as such, small-molecule inhibition of the BET family bromodomain-KAc protein-protein interaction has received significant interest as a therapeutic strategy, with several potential medicines under clinical evaluation. This work describes the structure- and property-based optimization of a ligand and lipophilic efficient pan-BET bromodomain inhibitor series to deliver candidate I-BET787 (70) that demonstrates efficacy in a mouse model of inflammation and suitable properties for both oral and intravenous (IV) administration. This focused two-phase explore-exploit medicinal chemistry effort delivered the candidate molecule in 3 months with less than 100 final compounds synthesized.

Legend

Protein

Chemical

Disease

Primary Citation of related structures